Search
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … orthogonal therapies) for the treatment of HIV-1 patients with resistant infections.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseDihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitDihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More RingsProducts: DITOL T JARABEAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.
Catheter-related Bloodstream Infection
go.drugbank.com/conditions/DBCOND0037994Synonyms: Bloodstream infection due to central venous catheterBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigational[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug … Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form.
Mixtures: BIMAPROS T, BEMATORİN-T 0,3 MG + 5 MG/1 ML GÖZ DAMLASI, ÇÖZELTİ, 1 ADETDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068]
Categories: Bile Salt Export Pump InhibitorsHuperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnIt is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease. … The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects.
Categories: Compounds used in a research, industrial, or household settingBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney. … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.
Iobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008. … The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline.
Categories: Compounds used in a research, industrial, or household settingProducts: IOBENGUANO [131 I] GE HEALTHCARE TFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy